Niacin and fibrate use among patients with high triglycerides and low high-density lipoprotein cholesterol

References

• Davidson MH, Toth PP. High-density lipoprotein metabolism: potential therapeutic targets. Am J Cardiol 2007;100:n32-40
   PubMed Web of Science ®Google Scholar
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
   Google Scholar
• Thom T, Haase N, Rosamond W, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006;113:e85-151
   Google Scholar
• Gaw A. Evidence based approach for the management of mixed hyperlipidaemia. Atherosclerosis 1998;137 (Suppl):S97-100
   PubMed Web of Science ®Google Scholar
• Birjmohun RS, van der Steeg WA, Stroes ESG, et al. The role of the high-density lipoprotein (HDL) particle in atherogenesis and potential methods to increase HDL concentrations. Ned Tijdschr Geneeskd 2006;150:2245-50
   PubMedGoogle Scholar
• Toth PP. When high is low: approaches to raising low high-density lipoprotein cholesterol levels. Curr Cardiol Rep 2008;10:488-96
   PubMedGoogle Scholar
• Ashen MD, Blumenthal RS. Low HDL cholesterol levels. N Engl J Med 2005;353:1252-60
   PubMed Web of Science ®Google Scholar
• Rizos E, Mikhalidis DP. Are high-density lipoprotein and triglyceride levels important in secondary prevention? Impressions from the BIP and VA-HIT trials. Int J Cardiol 2002;82:199-207
   PubMed Web of Science ®Google Scholar
• Miller M, Ginsberg HN, Schaefer EJ. Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. Am J Cardiol 2008;101:1003-8
   PubMed Web of Science ®Google Scholar
• Gordon D, Probstfield J, Garrison R, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989;79:8-15
   PubMed Web of Science ®Google Scholar
• BIP InvestigatorsSecondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21-7
   PubMed Web of Science ®Google Scholar
• Goldenberg I, Goldbourt U, Boyko V, et al.; BIP Study Group. Relation between on-treatment increments in serum high density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial). Am J Cardiol 2006;97:466-71
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards in medical care in diabetes–2006 (Position Statement). Diabetes Care 2006;29:4-42
   PubMed Web of Science ®Google Scholar
• Esposito K, Marfella R, Ciotola M, et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in metabolic syndrome: a randomized trial. JAMA 2004;292:1440-6
   PubMed Web of Science ®Google Scholar
• Toth PP. High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies. Am J Cardiol 2005;96:50-8K
   PubMed Web of Science ®Google Scholar
• Tenenbaum A, Fisman E, Motro M, et al. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. Cardiovasc Diabetol 2006;5:20
   PubMed Web of Science ®Google Scholar
• Fazio S. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy. Clin Ther 2008;30:294-306
   PubMed Web of Science ®Google Scholar
• Vittone F, Chait A, Morse JS, et al. Niacin plus simvastatin reduces coronary stenosis progression among patients with metabolic syndrome despite a modest increase in insulin resistance: a subgroup analysis of the HDL-Atherosclerosis Treatment Study (HATS). J Clin Lipidol 2007;1:203-10
   PubMed Web of Science ®Google Scholar
• Assmann G, Schulte H, Funke H, et al. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 1998;19:8-14
   PubMedGoogle Scholar
• Grundy SM. Consensus statement: role of therapy with 'statins' in patients with hypertriglyceridemia. Am J Cardiol 1998;81:1B-6B
   PubMed Web of Science ®Google Scholar
• Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-19
   PubMedGoogle Scholar
• Goldberg AC. Combination therapy of dyslipidemia. Curr Treat Options Cardiovasc Med 2007;9:249-58
   PubMedGoogle Scholar
• Parhofer KG. Beyond LDL-cholesterol: HDL-cholesterol as a target for atheroscleross prevention. Exp Clin Endocrinol Diabetes 2005;113:414-7
   PubMed Web of Science ®Google Scholar
• Bersot T, Haffner S, Harris WS, et al. Hypertriglyceridemia: management of atherogenic dyslipidemia. J Fam Pract 2006;55:S1-8
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007;298:299-308
   PubMed Web of Science ®Google Scholar
• Castelli WP, Anderson K, Wilson PW, et al. Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol 1992;2:23-8
   PubMedGoogle Scholar
• Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007;115:450-8
   PubMed Web of Science ®Google Scholar
• Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-9
   PubMedGoogle Scholar
• La Rosa JC. Triglycerides and coronary risk in women and the elderly. Arch Intern Med 1997;157:961-8
   PubMed Web of Science ®Google Scholar
• Wascher TC. The era of statins – is there still a place for other classes of lipid-lowering drugs? Heart Drug 2005;5:34-8
   Google Scholar
• Robins SJ, Collins D, Wittes JT, et al. ; VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001;285:1585-91
   PubMed Web of Science ®Google Scholar
• Miller M, Cannon CP, Murphy SA, et al. ; PROVE IT-TIMI 22 investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008;51:724-30
   PubMed Web of Science ®Google Scholar
• Klingman D, Williams SA, Benner JS, et al. Gauging the treatment gap in dyslipidemia: findings from the 1999-2000 National Health and Nutrition Examination Survey. Am Heart J 2005;150:595-601
   PubMed Web of Science ®Google Scholar
• Davidson MH. Differences between clinical trial efficacy and real-world effectiveness. Am J Manag Care 2006;12:S405-11
   PubMed Web of Science ®Google Scholar
• Goebel LJ, Bailony F, Khattak AJ, et al. Physician and patient barriers to adherence with cholesterol guidelines. W V Med J 2006;102:23-6
   PubMedGoogle Scholar
• Toth PP, Harper CR, Jacobson TA. Clinical characterization and molecular mechanisms of statin myopathy. Expert Rev Carodiovasc Ther 2008;6:955-69
   PubMedGoogle Scholar
• Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005;95:120-2
   PubMed Web of Science ®Google Scholar
• Stacy TA, Egger A. Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs. J. Manag Care Pharm 2006;12:745-51
   PubMed Web of Science ®Google Scholar
• Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
   PubMed Web of Science ®Google Scholar